LivaNova公共 LIVN 深 沪
等待开盘 09-23 09:30:00 美东时间
55.13
+0.130
+0.24%
华盛通- 最 高55.27
- 今 开54.81
- 成交量 45.12万股
- 最 低 54.04
- 昨 收 55.00
- 总市值 30.06亿
- 52周最高 58.91
- 市盈率 静 47.58
- 换手率 0.83%
- 52周最低 32.48
- 委 比 -87.92%
- 总股本 5452.57万
- 历史最高 131.54
- 量 比 0.72
- 振 幅 2.24%
- 历史最低 23.58
- 每 手 1
- 风险率 5.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Needham Reiterates Buy on LivaNova, Maintains $64 Price Target
Needham analyst Mike Matson reiterates LivaNova (NASDAQ:LIVN) with a Buy and maintains $64 price target.
09-03 19:58
Barclays Maintains Equal-Weight on LivaNova, Raises Price Target to $58
Barclays analyst Matt Miksic maintains LivaNova (NASDAQ:LIVN) with a Equal-Weight and raises the price target from $55 to $58.
08-21 22:45
LivaNova shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 guidance.
LivaNova shares are trading higher after the company reported better-than-expec...
08-06 23:31
Shopify, Astera Labs, Myriad Genetics, Grocery Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mostly higher, with the Dow Jones index gaining around 0.1% on...
08-06 22:42
LivaNova Raises FY2025 Adj EPS Guidance from $3.60-$3.70 to $3.70-$3.80 vs $3.65 Est; Raises FY2025 Sales Guidance from $1.316B-$1.341B to $1.353B-$1.366B vs $1.328B Est
LivaNova (NASDAQ:LIVN) raises FY2025 Adj EPS guidance from $3.60-$3.70 to $3.70-$3.80 vs $3.65 analyst estimate. Raises FY2025 sales outlook from $1.316 billion-$1.341 billion to $1.353 billion-$1.366 billion vs $1.328
08-06 18:02
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
LivaNova Shareholders Approve Key Incentive Plans at AGM
LivaNova ( ($LIVN) ) has issued an announcement. On June 11, 2025, LivaNova PLC...
06-12 05:17
LivaNova Initiates Process With U.S. CMS To Seek Reconsideration Of National Medicare Coverage For VNS Therapy In Unipolar Patients With Treatment-Resistant Depression
Final critical papers on RECOVER clinical study data accepted, supporting the Company's submission for coverage reconsideration Strong 24-month top-line data for RECOVER clinical study demonstrates durability of VNS Therapy In-depth analysis on suicidality at 12 months yields positive results
06-04 20:12
美股大行评级 | 潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
05-21 16:44
